Skip to main content

Table 1 Baseline demographic and clinical data.

From: Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy

Variables

All patients (n = 42)

Responders (n = 29, 69%)

Non-Responders (n = 13, 31%)

P Value

Demographic data

    

   Age, years

66 ± 12

66 ± 11

66 ± 15

0.83

   Male, n (%)

30 (68)

19 (65)

10 (77)

0.45

   CAD, n (%)

30 (68)

18 (62)

11 (85)

0.13

Clinical data

    

   QRS duration, ms

159 ± 28

162 ± 27

155 ± 30

0.51

   LBBB, n (%)

27 (61)

19 (65)

6 (46)

0.24

   RBBB, n (%)

2 (4.5)

2 (7)

0 (0)

...

   IVCD, n (%)

8 (18)

3 (10)

5 (38)

0.04

   PR, ms

180 ± 40

172 ± 32

195 ± 51

0.08

   Pre-CRT pacing, n (%)

7 (16)

5 (17)

2 (15)

0.88

   NYHA III/IV, n (%)

31 (70)/13 (30)

22 (76)/7 (24)

7 (54)/6 (46)

0.16

Medication

    

   Diuretic, n (%)

41 (93)

27 (93)

12 (92)

0.93

   β-Blockers, n (%)

41 (93)

26 (90)

13 (100)

0.13

   ACEi, n (%)

31 (70)

20 (69)

10 (77)

0.59

   AR Blockers, n (%)

13 (30)

9 (32)

3 (23)

0.55

   Digoxin, n (%)

11 (25)

5 (17)

6 (46)

0.06

   Spironolactone, n (%)

26 (59)

15 (52)

10 (77)

0.12

  1. CAD indicates coronary arteries disease, LBBB, left bundle branch block, RBBB, right bundle branch block, IVCD, intraventricular conduction defect, ACEi, angiotensin converting enzyme inhibitors and AR, angiotensin receptors.